Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
| ▸ | FLT4 | P35916 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.45 |
| ▸ | EDNRA | P25101 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38664258 | 1.00 | GAA (0.53) | GAAALDH1A1TSHRHSD17B10L3MBTL1 | |
| SCHEMBL1427884 | 0.84 | CA1 (0.48) | GAA | |
| SCHEMBL6255940 | 0.83 | PTGES2 (0.58) | TSHRPGRPTGES2 | |
| SCHEMBL6928314 | 0.82 | ALDH1A1 (0.56) | GAAALDH1A1TSHRHSD17B10L3MBTL1 | |
| SCHEMBL6255287 | 0.80 | HSD11B1 (0.56) | GAAALDH1A1LMNAEDNRAPTGES2 | |
| SCHEMBL5806023 | 0.80 | ALDH1A1 (0.55) | GAAALDH1A1TSHRHSD17B10L3MBTL1 | |
| SCHEMBL23747022 | 0.78 | ALDH1A1 (0.53) | GAAALDH1A1TSHRHSD17B10L3MBTL1 | |
| SCHEMBL2371935 | 0.78 | GAA (0.58) | GAAALDH1A1TSHRHSD17B10L3MBTL1 | |
| SCHEMBL1767992 | 0.78 | CA1 (0.55) | GAAALDH1A1TSHRHSD17B10L3MBTL1 | |
| Potassium SCHEMBL9789251 | 0.78 | ALDH1A1 (0.53) | GAAALDH1A1TSHRHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117535689-A | Method for synthesizing sulfonamide through decarbonylation of N, N-dimethylformamide and denitrification of sulfonyl hydrazide under electrochemical condition | 湘潭大学 | 2024-02-09 | — | — | CN | claimed |
| CN-107043340-A | A kind of method prepared to chlorobenzenesulfonyl hydrazine | 重庆锦杉科技有限公司 | 2017-08-15 | — | — | CN | claimed |
| CN-105218540-B | A kind of preparation method of 3 thiocarbamoyl imidazoles of C simultaneously [1,2 a] pyridine compounds and their | 曲阜师范大学 | 2017-07-04 | — | — | CN | claimed |
| CN-105218540-A | The preparation method of a kind of C-3 position thiocarbamoyl imidazole also [1,2-a] pyridine compounds and their | UNIV QUFU NORMAL | 2016-01-06 | — | — | CN | claimed |
| EP-1320523-B1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER LAMBERT CO (US) | 2005-06-22 | — | — | EP | claimed |
| US-20050014841-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | HU LAIN-YEN (US) | 2005-01-20 | — | — | US | claimed |
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | claimed |
| US-6809119-B2 | FOR USE AS AS NEURO-PROTECTIVE AGENTS FOR THERAPY OF CONDITIONS SUCH AS STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMINOGLYCOSIDE ANTIBIOTICS-INDUCED HEARING LOSS, MIGRAINE | WARNER-LAMBERT COMPANY LLC | 2004-10-26 | — | — | US | claimed |
| US-20030149110-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | HU LAIN-YEN (US) | 2003-08-07 | — | — | US | claimed |
| EP-1320523-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Warner-Lambert Company LLC (US) | 2003-06-25 | — | — | EP | claimed |
| WO-2003045902-A1 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2003-06-05 | — | — | WO | claimed |
| EP-1314723-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | WARNER-LAMBERT COMPANY (US) | 2003-05-28 | — | — | EP | claimed |
| WO-2002024672-A2 | BRANCHED CHAIN AMINO ACID-DEPENDENT AMINOTRANSFERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARNER-LAMBERT COMPANY LLC (US) | 2002-03-28 | — | — | WO | claimed |
| CN-118184582-A | 4-Seleno-1-benzenesulfonyl pyrazole compound and electrochemical synthesis method and application thereof | 延安大学 | 2024-06-14 | — | — | CN | disclosed |
| WO-2024040754-A1 | METHOD FOR SYNTHESIZING CIS-2-METHYL-7-OCTADECENE AND CIS-7,8-EPOXY-2-METHYLOCTADECANE | 南京蕃茂生物科技有限公司 | 2024-02-29 | — | — | WO | disclosed |
| CN-117535689-A | Method for synthesizing sulfonamide through decarbonylation of N, N-dimethylformamide and denitrification of sulfonyl hydrazide under electrochemical condition | 湘潭大学 | 2024-02-09 | — | — | CN | disclosed |
| EP-0101197-A2 | Method for preparing foam using cobalt/potassium promoters | UNIROYAL, INC. (US) | 1984-02-22 | — | — | EP | disclosed |
| US-4401771-A | HYDROCARBYLSULFONYL HYDRAZIDE FOAMING AGENT | UNIROYAL, INC. (US) | 1983-08-30 | — | — | US | disclosed |
| EP-0055087-A1 | Compositions and methods for producing expanded and cured polyester resin | UNIROYAL, INC. (US) | 1982-06-30 | — | — | EP | disclosed |
| US-4327196-A | USING SULFONYL HYDRAZIDE BLOWING AGENTS, PEROXIDE CURING AGENTS FOR SIMULTANEOUS FOAMING AND CURING | UNIROYAL, INC. (US) | 1982-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149110-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | BCAT1, BCAT2, ABAT | GAA 52/4885ALDH1A1 812/4885TSHR 3661/4885 |
| US-20050004167-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | BCAT1, BCAT2, ABAT | GAA 45/4885ALDH1A1 642/4885TSHR 3628/4885 |
| US-20050014841-A1 | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases | BCAT1, BCAT2, ABAT | GAA 52/4885ALDH1A1 812/4885TSHR 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.